What are the mechanism of action, half‑life, interactions with P‑glycoprotein (P‑gp) and cytochrome P450 2D6 (CYP2D6), and the effects on the QT interval and cardiac conduction of ketamine?

Ketamine: Pharmacologic Profile and Cardiac Effects

Ketamine is a non-selective, non-competitive NMDA receptor antagonist with a complex pharmacologic profile that includes minimal direct effects on cardiac conduction but significant indirect cardiovascular stimulation through catecholamine reuptake inhibition, and while it does not directly prolong QT interval, it has no clinically significant interactions with P-glycoprotein and is metabolized primarily by CYP2B6 and CYP3A4 (not CYP2D6). 1

Mechanism of Action

Ketamine functions primarily as an antagonist of N-methyl-D-aspartate (NMDA) receptors, an ionotropic glutamate receptor in the central nervous system 1. This produces its characteristic dissociative anesthetic state with profound analgesia while preserving protective airway reflexes 1. The drug also interacts with opioid, monoaminergic, and cholinergic systems, contributing to its analgesic and neuroprotective properties 2.

The major circulating metabolite, norketamine, demonstrates activity at the same NMDA receptor but with approximately one-third the potency of the parent compound 1.

Half-Life

Ketamine exhibits biphasic elimination kinetics 1:

• Alpha phase (distribution): 10-15 minutes half-life, corresponding to the clinical anesthetic effect
• Beta phase (redistribution): 2.5 hours half-life, representing redistribution from the CNS to peripheral tissues and hepatic metabolism

The initial 45-minute concentration slope reflects rapid redistribution and accounts for the drug's short duration of action 1.

CYP450 Metabolism (Not CYP2D6)

Ketamine is metabolized primarily by CYP2B6 and CYP3A4, not CYP2D6 1. This is a critical distinction:

• N-dealkylation to norketamine occurs via CYP2B6 and CYP3A4 as the primary enzymes
• Other CYP enzymes contribute to a lesser extent
• Norketamine undergoes further hydroxylation via CYP-dependent pathways to form hydroxynorketamine compounds
• These metabolites are conjugated with glucuronic acid and undergo dehydration to form dehydroxynorketamine 1

Clinical implication: Drug interactions should focus on CYP2B6 and CYP3A4 inhibitors/inducers, not CYP2D6 polymorphisms or interactions.

P-Glycoprotein Interactions

No clinically significant P-glycoprotein interactions are documented in the FDA label or available evidence 1. The drug's pharmacokinetic profile is determined by hepatic metabolism rather than transporter-mediated efflux.

Effects on QT Interval

The evidence regarding ketamine's effect on QT interval shows dose-dependent and context-specific effects:

Key Findings:

• At standard anesthetic doses, ketamine produces minimal to no clinically significant QT prolongation when used alone 1

• In cardiac surgery patients, the propofol-ketamine combination showed QTc prolongation compared to midazolam-fentanyl, but this may reflect propofol's contribution 3

• During electroconvulsive therapy, ketamine produced less QT prolongation than sevoflurane at multiple time points post-stimulus 4

• High-dose esketamine (0.5 mg/kg/h) demonstrated prolonged monophasic action potential triangulation and electrical alternans in experimental models, suggesting arrhythmogenic potential at supra-therapeutic doses 5

Clinical context: Unlike many psychotropic medications that directly inhibit hERG channels 6, ketamine's cardiovascular effects are primarily mediated through sympathomimetic activity rather than direct ion channel blockade 1. The QT changes observed are typically secondary to heart rate and hemodynamic alterations rather than direct repolarization effects.

Effects on Cardiac Conduction

Ketamine produces indirect cardiovascular stimulation rather than direct conduction effects 1:

Cardiovascular Pharmacodynamics:

• Increases blood pressure, heart rate, and cardiac output through inhibition of central and peripheral catecholamine reuptake 1
• Blood pressure peaks 10-50% above baseline within minutes of injection, returning to baseline within 15 minutes in most cases 1
• Preserves or enhances cardiac output, making it advantageous in hemodynamically unstable patients 2

Conduction System Effects:

• No direct effects on AV nodal conduction or His-Purkinje system are documented in the FDA label 1
• Experimental data show dose-dependent effects on action potential morphology: increased resting membrane potential, reduced action potential amplitude, and decreased maximum upstroke velocity (Vmax) 5
• At therapeutic doses (0.125 mg/kg/h), ketamine increased heart rate and conduction velocity without detectable arrhythmias 5
• At higher doses (0.5 mg/kg/h), conduction heterogeneities and decreased Connexin43 expression were observed, suggesting potential for conduction disturbances with prolonged high-dose infusions 5

Clinical Implications:

Ketamine is cardiovascularly favorable in most emergency and anesthetic contexts because it maintains hemodynamic stability and does not depress cardiac conduction like many other sedatives 2, 7. However, caution is warranted in patients with:

• Uncontrolled hypertension (sympathomimetic effects may exacerbate)
• Coronary artery disease with active ischemia (increased myocardial oxygen demand)
• Prolonged high-dose infusions in critically ill patients (potential for conduction heterogeneity) 5

Comparison to Other Agents:

Unlike propofol (which causes bradycardia and hypotension) or volatile anesthetics (which prolong QT and depress conduction), ketamine maintains sympathetic tone and cardiac output, making it particularly useful in trauma, shock, and hemodynamically unstable patients 2, 7.